-
-
-
-
-
-
-
Oppenheimer Downgrades Capricor Therapeutics (CAPR) to Perform
-
-
-
-
-
-
-
Alliance Global Partners Downgrades Capricor Therapeutics (CAPR) to Neutral
-
-
-
-
-
-
-
Oppenheimer Reiterates Capricor Therapeutics (CAPR) at Outperform, 'like the risk-reward'
-
-
-
-
-
-
-
Capricor sues NS Pharma over Duchenne therapy distribution deal
-
-
-
-
-
-
-
Truist on Head of CBER at FDA Exit: 'we anticipate a positive stock reaction for IRON CAPT RGNX QURE'
-
-
-
-
-
-
-
Piper Sandler: 'We Are Naming Capricor Therapeutics (CAPR) As a 2026 Top Pick'
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Halted, News Pending
-
443,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

